The oncology landscape is undergoing its most significant transformation since the advent of checkpoint inhibitors, driven by the clinical and commercial success of mRNA technology. Unlike traditional vaccines that prevent disease, therapeutic mRNA cancer vaccines are designed to train the patient’s own immune system to identify and destroy malignant cells. The mRNA Cancer Vaccines...

The vaccine market is becoming an increasingly strategic component of preventive healthcare as governments, healthcare organizations, and pharmaceutical companies continue to prioritize immunization, outbreak preparedness, and long-term disease prevention. The market was valued at USD 72.8 billion in 2025 and is estimated to reach USD 78.1 billion in 2026, before expanding to USD 115.8 billion...